

Human ALK-7/Activin RIC Protein

Cat. No. ALK-HM207



Description

Source	Recombinant Human ALK-7/Activin RIC Protein is expressed from HEK293 with hFc tag at the C-terminus. It contains Glu21-Glu113.
Accession	Q8NER5-1
Molecular Weight	The protein has a predicted MW of 35.96 kDa. Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Arterial stiffness is an important feature of diabetic macrovascular complications. Activin receptor-like kinase 7 (ALK7), a member of type I transforming growth factor- β (TGF- β) receptors, is correlated with pathogenic risks of type 2 diabetes mellitus and cardiovascular diseases and may be involved in cardiovascular remodeling.

Assay Data


Bis-Tris PAGE



Human ALK-7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC


Assay Data



The purity of Human ALK-7 is greater than 95% as determined by SEC-HPLC.

ELISA Data

Human ALK-7, hFc Tag ELISA
0.1µg Human ALK-7, hFc Tag Per Well



Immobilized Human ALK-7, hFc Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Biotinylated Anti-ALK-7 Antibody, hFc Tag with the EC50 of 4.1ng/ml determined by ELISA.